| Quarterly Financials | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 412 | 525 | 519 | 483 | 486 | 545 | 489 | 565 | 542 | 599 | 531 | 637 | 555 | 714 | 732 | 841 | 981 | 1,144 | 1,295 | 1,417 | 1,284 | 1,206 | 1,034 | 1,426 | 1,541 | 1,577 | 1,546 | 1,383 | 1,185 | 1,226 | 1,197 | 1,458 | 1,197 | 1,228 | 1,425 |
| Expenses | 325 | 408 | 406 | 358 | 382 | 426 | 392 | 443 | 459 | 513 | 442 | 523 | 467 | 575 | 581 | 647 | 696 | 765 | 862 | 940 | 883 | 858 | 744 | 1,028 | 1,085 | 1,127 | 1,141 | 1,095 | 1,015 | 1,037 | 1,014 | 1,198 | 1,024 | 1,045 | 1,130 |
| EBITDA | 87 | 116 | 112 | 125 | 104 | 119 | 97 | 122 | 83 | 86 | 89 | 114 | 88 | 139 | 150 | 194 | 285 | 379 | 433 | 477 | 401 | 348 | 291 | 398 | 456 | 450 | 405 | 287 | 170 | 190 | 184 | 260 | 174 | 183 | 295 |
| Operating Profit % | 21 % | 21 % | 20 % | 24 % | 20 % | 21 % | 18 % | 21 % | 15 % | 13 % | 17 % | 18 % | 15 % | 19 % | 20 % | 23 % | 29 % | 33 % | 33 % | 33 % | 31 % | 29 % | 28 % | 28 % | 30 % | 28 % | 26 % | 21 % | 14 % | 15 % | 15 % | 17 % | 14 % | 15 % | 20 % |
| Depreciation | 25 | 26 | 27 | 28 | 30 | 30 | 31 | 35 | 38 | 40 | 43 | 44 | 46 | 48 | 48 | 46 | 49 | 51 | 52 | 54 | 59 | 63 | 64 | 66 | 71 | 82 | 84 | 87 | 91 | 93 | 98 | 102 | 106 | 108 | 106 |
| Interest | 28 | 25 | 31 | 17 | 19 | 20 | 18 | 23 | 22 | 25 | 24 | 18 | 23 | 26 | 21 | 21 | 15 | 14 | 17 | 22 | 27 | 22 | 23 | 31 | 29 | 40 | 43 | 53 | 39 | 42 | 51 | 51 | 49 | 53 | 58 |
| Profit Before Tax | 35 | 66 | 54 | 81 | 55 | 70 | 49 | 64 | 23 | 22 | 23 | 53 | 19 | 66 | 82 | 127 | 222 | 314 | 364 | 401 | 316 | 263 | 204 | 302 | 356 | 328 | 278 | 147 | 41 | 54 | 35 | 107 | 19 | 23 | 131 |
| Tax | 9 | 18 | 9 | 9 | 16 | 21 | 14 | 19 | 6 | 6 | 5 | 9 | 4 | 9 | 8 | 17 | 50 | 72 | 91 | 104 | 74 | 59 | 49 | 70 | 104 | 95 | 75 | 42 | 14 | 17 | 11 | 32 | 6 | 3 | 38 |
| Net Profit | 26 | 48 | 45 | 71 | 39 | 49 | 35 | 45 | 17 | 16 | 18 | 43 | 15 | 57 | 74 | 110 | 172 | 242 | 273 | 297 | 242 | 204 | 155 | 232 | 252 | 233 | 203 | 105 | 27 | 37 | 23 | 75 | 13 | 20 | 93 |
| EPS in ₹ | 3.73 | 5.18 | 4.50 | 6.75 | 3.68 | 4.61 | 3.29 | 4.26 | 1.56 | 1.53 | 1.67 | 4.07 | 1.42 | 1.06 | 1.38 | 2.06 | 3.21 | 4.53 | 5.09 | 5.53 | 4.50 | 3.76 | 2.87 | 4.29 | 4.68 | 4.33 | 3.78 | 1.90 | 0.46 | 0.69 | 0.43 | 1.40 | 0.23 | 0.37 | 1.71 |
Laurus Labs
615.15
-7.85
(-1.26%)
Market Cap
33,589.60 Cr
EPS
2.98
PE Ratio
165.69
Dividend Yield
0.13 %
Industry
Healthcare52 Week High
646.20
52 Week Low
385.45
PB Ratio
8.02
Debt to Equity
0.56
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,764.75 | 4,28,233.30 | 35.92 | 49,887.20 | 12.06 | 9,648 | 13.77 | 61.58 | |
| 5,840.65 | 1,56,910.50 | 74.97 | 8,184.00 | 0.89 | 1,600 | 64.53 | 55.23 | |
| 1,511.20 | 1,23,084.40 | 24.45 | 26,520.70 | 14.17 | 4,155 | 47.38 | 60.28 | |
| 3,245.05 | 1,10,720.70 | 58.75 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.68 | |
| 1,177.90 | 1,00,988.70 | 18.34 | 28,905.40 | 12.36 | 5,578 | 1.69 | 51.86 | |
| 2,398.05 | 97,867.10 | 48.47 | 10,615.60 | 19.57 | 1,942 | -16.38 | 56.07 | |
| 2,068.75 | 96,711.60 | 32.93 | 20,141.50 | 19.94 | 1,936 | 38.82 | 54.50 | |
| 907.35 | 92,945.80 | 20.14 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.54 | |
| 1,194.95 | 70,253.80 | 19.68 | 29,559.20 | 17.55 | 3,169 | -10.04 | 61.05 | |
| 31,101.85 | 66,026.50 | 49.49 | 6,097.20 | 10.80 | 1,201 | 16.01 | 61.04 |
Growth Rate
Revenue Growth
-16.20 %
Net Income Growth
-78.89 %
Cash Flow Change
-33.02 %
ROE
-79.22 %
ROCE
-67.38 %
EBITDA Margin (Avg.)
-39.99 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 |
| Fixed Assets | 801 | 1,021 | 1,230 | 1,481 | 1,629 | 1,726 | 2,171 | 2,653 | 3,409 | 3,890 |
| Current Assets | 865 | 1,003 | 1,140 | 1,248 | 1,463 | 1,812 | 3,075 | 3,345 | 3,462 | 3,835 |
| Capital Work in Progress | 110 | 70 | 143 | 163 | 110 | 67 | 362 | 813 | 551 | 423 |
| Investments | 0 | 7 | 3 | 3 | 3 | 3 | 3 | 31 | 50 | 124 |
| Other Assets | 983 | 1,126 | 1,277 | 1,369 | 1,589 | 1,953 | 3,215 | 3,472 | 3,651 | 3,950 |
| Total Liabilities | 1,894 | 2,224 | 2,653 | 3,017 | 3,331 | 3,750 | 5,751 | 6,968 | 7,660 | 8,387 |
| Current Liabilities | 805 | 884 | 1,121 | 1,307 | 1,424 | 1,692 | 2,457 | 2,681 | 2,432 | 3,112 |
| Non Current Liabilities | 365 | 483 | 202 | 227 | 349 | 288 | 693 | 928 | 1,180 | 1,159 |
| Total Equity | 724 | 857 | 1,330 | 1,483 | 1,558 | 1,770 | 2,601 | 3,359 | 4,049 | 4,116 |
| Reserve & Surplus | 642 | 774 | 1,225 | 1,371 | 1,447 | 1,658 | 2,490 | 3,244 | 3,930 | 4,003 |
| Share Capital | 82 | 82 | 106 | 106 | 106 | 107 | 107 | 108 | 108 | 108 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 24 | -27 | -10 | 1 | 0 | -1 | 47 | 27 | -30 | 93 |
| Investing Activities | -397 | -312 | -289 | -384 | -253 | -221 | -941 | -915 | -997 | -822 |
| Operating Activities | -65 | 182 | 332 | 343 | 298 | 347 | 733 | 911 | 994 | 666 |
| Financing Activities | 486 | 103 | -54 | 42 | -45 | -128 | 255 | 30 | -27 | 250 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 27.45 % | 27.30 % | 27.30 % | 27.27 % | 27.27 % | 27.27 % | 27.27 % | 27.20 % | 27.20 % | 27.20 % | 27.20 % | 27.19 % | 27.19 % | 27.18 % | 27.18 % | 27.62 % |
| FIIs | 0.00 % | 0.04 % | 0.04 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 0.02 % | 0.02 % | 0.00 % | 0.00 % | 0.00 % | 25.97 % | 25.67 % | 26.08 % | 25.56 % |
| DIIs | 2.06 % | 2.40 % | 2.11 % | 2.77 % | 3.51 % | 4.77 % | 8.98 % | 9.51 % | 9.74 % | 10.14 % | 10.71 % | 10.77 % | 11.77 % | 13.56 % | 13.05 % | 12.74 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 34.17 % | 34.18 % | 32.91 % | 32.87 % | 31.15 % | 28.42 % | 27.96 % | 28.95 % | 28.49 % | 28.26 % | 26.49 % | 25.01 % | 23.95 % | 22.68 % | 22.67 % | 22.72 % |
| Others | 36.32 % | 36.07 % | 37.65 % | 37.08 % | 38.05 % | 39.53 % | 35.80 % | 34.32 % | 34.55 % | 34.39 % | 35.60 % | 37.03 % | 11.12 % | 10.91 % | 11.03 % | 11.36 % |
| No of Share Holders | 2,35,836 | 2,99,257 | 3,94,053 | 4,67,419 | 4,27,465 | 4,07,186 | 3,90,695 | 4,23,931 | 4,18,615 | 4,17,977 | 4,02,640 | 3,82,880 | 3,56,830 | 3,24,059 | 3,09,063 | 2,92,214 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1.5 | 1.5 | 1.5 | 2.5 | 2 | 2 | 2 | 0.8 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.49 | 1.88 | 2.31 | 0.69 | 0.34 | 0.67 | 0.51 | 0.13 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Rumour verification - Regulation 30(11)
Clarification sought from Laurus Labs Ltd
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Results For The Quarter Ended 31.12.2024
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
General Updates
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Investor Presentation
Corporate Action-Board approves Dividend
Board Meeting Outcome for Interim Dividend FY 2024-25
Results - Half Year Ended September 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2024 And The Proposal For Payment Of Interim Dividend For FY 2024-25
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Announcement under Regulation 30 (LODR)-Change in Directorate
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Laurus Labs Concludes Successful USFDA Audit For API Manufacturing Facility At Hyderabad
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Technical Indicators
RSI(14)
Neutral 60.99
ATR(14)
Less Volatile 20.95
STOCH(9,6)
Overbought 90.30
STOCH RSI(14)
Overbought 93.26
MACD(12,26)
Bullish 6.66
ADX(14)
Weak Trend 15.88
UO(9)
Bearish 62.65
ROC(12)
Uptrend But Slowing Down 5.96
WillR(14)
Overbought -13.99
About Laurus Labs
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs has four manufacturing facilities in Visakhapatnam, Andhra Pradesh, producing APIs, ingredients, and Finished Dosage Formulations (FDFs). The company serves global pharmaceutical markets, particularly in Sub-Saharan Africa, South-East Asia, and Latin America. Laurus Labs also offers contract development and manufacturing services, and produces specialty ingredients for the nutraceutical and cosmeceutical sectors. The company has expanded its operations through acquisitions, partnerships, and investments in new facilities and capabilities.
Listing Date
19 Dec, 2016(8 Years,
35 days)
Website
Chairperson NameRavindranath Kancherla
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
